Compass Therapeutics to Present at Upcoming Investment Conferences

Rhea-AI Summary

BOSTON, Nov. 08, 2022 - Compass Therapeutics, Inc. (Nasdaq: CMPX) announced its participation in two key investor conferences this November. The Stifel Healthcare Conference in New York City is scheduled for November 15, 2022, from 4:10-4:40 PM ET. The Jefferies Global Healthcare Conference in London will take place on November 16, 2022, from 3:15-3:45 PM GMT. Both presentations will be available via webcast, with a replay accessible for 90 days. Compass Therapeutics focuses on developing antibody-based therapies targeting cancer.

BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced it will be presenting at the following investor conferences during the month of November 2022.

Presentation details are as follows:

Stifel Healthcare Conference in New York City
Date: Tuesday, November 15, 2022
Time: 4:10-4:40 PM ET
Webcast Link: https://wsw.com/webcast/stifel74/cmpx/2109872

Jefferies Global Healthcare Conference in London, UK
Date: Wednesday, November 16, 2022
Time: 3:15 – 3:45 PM GMT
Webcast Link: https://wsw.com/webcast/jeff255/cmpx/1866024

Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’ Events page.

About Compass Therapeutics

Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.

Investor Contact
Mario Corso, Executive Director and Head of Investor Relations
ir@compasstherapeutics.com

Media Contact
Anna Gifford, Communications Manager
media@compasstherapeutics.com
617-500-8099

FAQ

When is Compass Therapeutics presenting at the Stifel Healthcare Conference?

Compass Therapeutics will present at the Stifel Healthcare Conference on November 15, 2022, from 4:10-4:40 PM ET.

What are the details for the Jefferies Global Healthcare Conference presentation by CMPX?

The Jefferies Global Healthcare Conference presentation by Compass Therapeutics (CMPX) is on November 16, 2022, from 3:15-3:45 PM GMT.

Where can I watch the Compass Therapeutics investor presentations?

The presentations by Compass Therapeutics will be available via webcasts, and replays can be accessed for 90 days.

What is the focus of Compass Therapeutics?

Compass Therapeutics is focused on developing proprietary antibody-based therapeutics for cancer treatment.

What is the stock symbol for Compass Therapeutics?

The stock symbol for Compass Therapeutics is CMPX.